<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Side effects of antidepressant medications&lt;sup&gt;[1-7]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Side effects of antidepressant medications<sup>[1-7]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Side effects of antidepressant medications<sup>[1-7]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="9" width="11%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Anticholinergic</td> <td class="subtitle1">Drowsiness</td> <td class="subtitle1">Insomnia/<br/> agitation</td> <td class="subtitle1">Orthostatic hypotension</td> <td class="subtitle1">QTc prolongation<sup>*</sup></td> <td class="subtitle1">Gastrointestinal toxicity</td> <td class="subtitle1">Weight gain</td> <td class="subtitle1">Sexual dysfunction</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Selective serotonin reuptake inhibitors<sup>¶</sup></td> </tr> <tr> <td class="indent1">Citalopram</td> <td>0</td> <td>0</td> <td>1+</td> <td>1+</td> <td>3+<sup>Δ</sup></td> <td>1+<sup>¶</sup></td> <td>1+</td> <td>3+</td> </tr> <tr> <td class="indent1">Escitalopram</td> <td>0</td> <td>0</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>1+<sup>¶</sup></td> <td>1+</td> <td>3+</td> </tr> <tr> <td class="indent1">Fluoxetine</td> <td>0</td> <td>0</td> <td>2+</td> <td>1+</td> <td>1+</td> <td>1+<sup>¶</sup></td> <td>0</td> <td>3+</td> </tr> <tr> <td class="indent1">Fluvoxamine</td> <td>0</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>1+<sup>¶</sup></td> <td>1+</td> <td>3+</td> </tr> <tr> <td class="indent1">Paroxetine</td> <td>1+</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>0 to 1+</td> <td>1+<sup>¶</sup></td> <td>2+</td> <td>4+</td> </tr> <tr> <td class="indent1">Sertraline</td> <td>0</td> <td>0</td> <td>2+</td> <td>1+</td> <td>1 to 2+</td> <td>2+<sup>¶◊</sup></td> <td>1+</td> <td>3+</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Atypical agents</td> </tr> <tr> <td class="indent1">Agomelatine<sup>§</sup> (not available in United States)</td> <td>0</td> <td>1+</td> <td>1+</td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>0 to 1+</td> </tr> <tr> <td class="indent1">Bupropion</td> <td>0</td> <td>0</td> <td> <p>2+ (immediate release)</p> 1+ (sustained release)</td> <td>0</td> <td>0 to 1+<sup>¥</sup></td> <td>1+</td> <td>0</td> <td>0</td> </tr> <tr> <td class="indent1">Mirtazapine</td> <td>1+</td> <td>4+</td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>4+</td> <td>1+</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Serotonin-norepinephrine reuptake inhibitors<sup>¶‡</sup></td> </tr> <tr> <td class="indent1">Desvenlafaxine<sup>†</sup></td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>0</td> <td>2+</td> <td>Unknown</td> <td>1+</td> </tr> <tr> <td class="indent1">Duloxetine</td> <td>0</td> <td>0</td> <td>1+</td> <td>0</td> <td>0</td> <td>2+<sup>¶</sup></td> <td>0 to 1+</td> <td>1+</td> </tr> <tr> <td class="indent1">Levomilnacipran<sup>†</sup></td> <td>0<sup>**</sup></td> <td>0</td> <td>0 to 1+</td> <td>0 to 1+</td> <td>0</td> <td>2+<sup>¶</sup></td> <td>0</td> <td>1+</td> </tr> <tr> <td class="indent1">Milnacipran<sup>†</sup></td> <td>0</td> <td>1+</td> <td>0</td> <td>0</td> <td>0</td> <td>2+<sup>¶</sup></td> <td>0</td> <td>1+</td> </tr> <tr> <td class="indent1">Venlafaxine<sup>†</sup></td> <td>0</td> <td>1+</td> <td>1+</td> <td>0</td> <td>0 to 1+<sup>¥</sup></td> <td>2+</td> <td>0 to 1+</td> <td>3+</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Serotonin modulators</td> </tr> <tr> <td class="indent1">Nefazodone<sup>¶¶</sup></td> <td>1+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>0</td> <td>2+</td> <td>0</td> <td>0</td> </tr> <tr> <td class="indent1">Trazodone</td> <td>0</td> <td>4+</td> <td>0</td> <td> <p>1+ (hypnotic dose)</p> 3+ (antidepressant dose)</td> <td>1 to 2+</td> <td> <p>1+ (hypnotic dose)</p> 3+ (antidepressant dose)</td> <td> <p>0 (hypnotic dose)</p> 1+ (antidepressant dose)</td> <td>1+<sup>ΔΔ</sup></td> </tr> <tr> <td class="indent1">Vilazodone</td> <td>0</td> <td>0</td> <td>2+</td> <td>0</td> <td>0</td> <td>4+<sup>◊◊</sup></td> <td>0</td> <td>1+</td> </tr> <tr> <td class="indent1">Vortioxetine</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>3+</td> <td>0</td> <td>1+</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Tricyclic and tetracyclic antidepressants</td> </tr> <tr> <td class="indent1">Amitriptyline</td> <td>4+</td> <td>4+</td> <td>0</td> <td>3+</td> <td>1 to 2+</td> <td>1+<sup>§§</sup></td> <td>4+</td> <td>3 to 4+</td> </tr> <tr> <td class="indent1">Amoxapine</td> <td>2+</td> <td>2+</td> <td>2+</td> <td>2+</td> <td>1+</td> <td>0<sup>§§</sup></td> <td>2+</td> <td>ND</td> </tr> <tr> <td class="indent1">Clomipramine</td> <td>4+</td> <td>4+</td> <td>1+</td> <td>2+</td> <td>3+</td> <td>1+<sup>§§</sup></td> <td>4+</td> <td>4+</td> </tr> <tr> <td class="indent1">Desipramine</td> <td>1+</td> <td>2+</td> <td>1+</td> <td>2+</td> <td>1 to 2+</td> <td>0<sup>§§</sup></td> <td>1+</td> <td>ND</td> </tr> <tr> <td class="indent1">Doxepin</td> <td>3+</td> <td>3+</td> <td>0</td> <td>2+</td> <td>3+</td> <td>0<sup>§§</sup></td> <td>4+</td> <td>3+</td> </tr> <tr> <td class="indent1">Imipramine</td> <td>3+</td> <td>3+</td> <td>1+</td> <td>4+</td> <td>3+</td> <td>1+<sup>§§</sup></td> <td>4+</td> <td>3+</td> </tr> <tr> <td class="indent1">Maprotiline</td> <td>2+</td> <td>3+</td> <td>0</td> <td>2+</td> <td>1+</td> <td>0<sup>§§</sup></td> <td>2+</td> <td>ND</td> </tr> <tr> <td class="indent1">Nortriptyline</td> <td>2+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>1 to 2+</td> <td>0<sup>§§</sup></td> <td>1+</td> <td>ND</td> </tr> <tr> <td class="indent1">Protriptyline</td> <td>2+</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>1+</td> <td>1+<sup>§§</sup></td> <td>1+</td> <td>3 to 4+</td> </tr> <tr> <td class="indent1">Trimipramine</td> <td>4+</td> <td>4+</td> <td>1+</td> <td>3+</td> <td>1+</td> <td>0<sup>§§</sup></td> <td>4+</td> <td>ND</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Monoamine oxidase inhibitors</td> </tr> <tr> <td class="indent1">Isocarboxazid</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>1+</td> <td>4+</td> </tr> <tr> <td class="indent1">Phenelzine</td> <td>1+</td> <td>2+</td> <td>1+</td> <td>3+</td> <td>0</td> <td>1+</td> <td>2+</td> <td>4+</td> </tr> <tr> <td class="indent1">Selegiline</td> <td>1+</td> <td>0</td> <td>1+</td> <td>1+</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td class="indent1">Tranylcypromine</td> <td>1+</td> <td>1+</td> <td>2+</td> <td>2+</td> <td>0</td> <td>1+</td> <td>1+</td> <td>4+</td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>Scale:</strong> 0 = none; 1+ = slight; 2+ = low; 3+ = moderate; 4+ = high; ND = inadequate data.</div><div class="graphic_footnotes"><p>SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitors.</p>
<p>* Relative mean QTc prolongation at therapeutic doses; arrhythmogenic potential can be significantly increased in overdose (eg, for cyclic antidepressants, bupropion, citalopram, duloxetine, venlafaxine, and some others). QTc prolongation classifications are based upon US Food and Drug Administration guidance.<sup>[6]</sup> The use of other classification criteria may lead to some agents being classified differently by other sources. Refer to UpToDate topics on acquired long QT syndrome and acute antidepressant poisonings.</p>
<p>¶ All SSRIs and SNRIs can cause transient nausea and gastrointestinal discomfort when starting therapy or increasing dose.</p>
<p>Δ Based upon reports of dose-related QTc prolongation and arrhythmia, the maximum recommended dose of citalopram is 40 mg/day in most patients; for patients at increased risk of elevated serum concentrations (eg, age &gt;60 years, significant hepatic impairment, receiving interacting medications), the maximum daily dose is 20 mg.</p>
<p>◊ Sertraline is associated with higher rates of diarrhea.</p>
<p>§ Agomelatine may be hepatotoxic and is contraindicated in any degree of liver impairment. Transaminase monitoring is required.</p>
<p>¥ Evidence of an association with QTc prolongation and arrhythmias is limited to overdose; available data on QTc effects of bupropion and venlafaxine at therapeutic doses are reassuring.</p>
<p>‡ SNRIs do not have significant anticholinergic effects. However, SNRIs can produce anticholinergic-like effects (which appear to be mediated by noradrenergic stimulation) such as dry mouth and constipation, and they should be used with caution in narrow angle glaucoma. Levomilnacipran is associated with urinary hesitancy.</p>
<p>† May cause persistent dose-related increases in blood pressure (primarily diastolic) and heart rate. Monitor blood pressure regularly.</p>
<p>** Levomilnacipran can cause dose-dependent urinary hesitancy.</p>
<p>¶¶ Caution: can cause liver failure; transaminase monitoring is required. Withdrawn from market due to hepatotoxicity in many countries.</p>
<p>ΔΔ Trazodone is associated rarely with priapism, which is considered a medical emergency. Refer to UpToDate topic on serotonin modulators.</p>
<p>◊◊ Gastrointestinal effects include nausea, vomiting, and diarrhea.</p>
§§ Gastrointestinal forms of anticholinergic side effects include: dry mouth, constipation, epigastric distress, decreased esophagogastric tone. Refer to "Anticholinergic" data column for frequency rankings.</div><div class="graphic_reference">References:
<ol>
<li>Wenzel-Seifert K, Wittmann M, Haen E: QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 2011; 108:687.</li>
<li>Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis. Drug Saf 2014; 37:19.</li>
<li>Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011; 34:709.</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
<li>Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30:242.</li>
<li>Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythic Potential for Non-Antiarrhythmic Drugs – Questions and Answers; Guidance for Industry US Food and Drug Administration, June 2017. Available at: <a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073161.pdf" target="_blank">https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073161.pdf</a>.</li>
<li>The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5<sup>th</sup> ed, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing 2017.</li>
</ol></div><div id="graphicVersion">Graphic 62488 Version 31.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
